Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series

摘要

Aim: Long-term survivors (LTS)?after glioma recurrence while on bevacizumab (Bev)?therapy are rarely reported in the current literature. The purpose of this case series is to confirm the existence of and describe a large cohort of recurrent glioma LTS treated with Bev (Bev-LTS). Patients & methods: We identified Bev-LTS as patients with post-Bev initiation survival times of ≥3 years among 1397 Bev treated recurrent glioma patients. Results: Among 962 grade-IV,?221 grade III, and?214 grade II Bev-treated glioma patients, we identified 28 (2.9%),?14 (6.3%) and?8?(3.7%)?Bev-LTS patients, respectively. 45?Bev-LTS patients recurred on Bev, with 36 of those patients continuing therapy.?Conclusion: Our study shows that a small portion of grade-IV, -III,?and -II glioma patients can have long-term survival on Bev therapy even after Bev recurrence.